MX2022012234A - Inhibidores de la caspasa para mejorar la reparación de lesiones y para tratar infecciones bacterianas o virales. - Google Patents
Inhibidores de la caspasa para mejorar la reparación de lesiones y para tratar infecciones bacterianas o virales.Info
- Publication number
- MX2022012234A MX2022012234A MX2022012234A MX2022012234A MX2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A
- Authority
- MX
- Mexico
- Prior art keywords
- viral infections
- injury repair
- treat bacterial
- caspase inhibitors
- caspase
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 3
- 102000011727 Caspases Human genes 0.000 title abstract 3
- 108010076667 Caspases Proteins 0.000 title abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 3
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 208000027418 Wounds and injury Diseases 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 title abstract 2
- 230000006378 damage Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000014674 injury Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 229940123169 Caspase inhibitor Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 206010040882 skin lesion Diseases 0.000 abstract 1
- 231100000444 skin lesion Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere al campo de la inhibición de la caspasa. Más específicamente, la presente invención proporciona composiciones y métodos que utilizan inhibidores de caspasa para mejorar la reparación de lesiones y tratar infecciones bacterianas y virales. En una modalidad específica, un método para tratar una infección bacteriana y lesiones cutáneas en un paciente comprende la etapa de administrar al paciente una cantidad eficaz de un inhibidor de caspasa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001674P | 2020-03-30 | 2020-03-30 | |
| PCT/US2021/024889 WO2021202530A1 (en) | 2020-03-30 | 2021-03-30 | Caspase inhibitors to enhance injury repair and to treat bacterial and viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012234A true MX2022012234A (es) | 2023-01-16 |
Family
ID=77929521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012234A MX2022012234A (es) | 2020-03-30 | 2021-03-30 | Inhibidores de la caspasa para mejorar la reparación de lesiones y para tratar infecciones bacterianas o virales. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230218705A1 (es) |
| EP (1) | EP4126010A4 (es) |
| JP (1) | JP2023520460A (es) |
| KR (1) | KR20230006480A (es) |
| CN (1) | CN115551536A (es) |
| AU (1) | AU2021245848A1 (es) |
| BR (1) | BR112022019850A2 (es) |
| CA (1) | CA3174364A1 (es) |
| IL (1) | IL296890A (es) |
| MX (1) | MX2022012234A (es) |
| WO (1) | WO2021202530A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4135845A2 (en) | 2020-04-14 | 2023-02-22 | Amerimmune, LLC | Treatment for diseases caused by rna viruses |
| IT202300000834A1 (it) | 2023-01-20 | 2024-07-20 | Scylla Biotech Srl | Inibitori selettivi della caspasi-8 ed usi degli stessi per potenziare le difese innate |
| CN116334213B (zh) * | 2023-04-03 | 2026-04-07 | 上海市东方医院(同济大学附属东方医院) | circ-0007527作为靶点在筛选用于治疗腹膜透析相关腹膜纤维化的药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03009647A (es) * | 2001-04-19 | 2004-01-29 | Vertex Pharma | Heterociclildicarbamidas como inhibidores de caspasa. |
| AU2007207434B2 (en) * | 2006-01-20 | 2012-04-05 | Reneuron, Inc. | Method of improving cell proliferation of pancreatic progenitor cells in a pancreatic cell culture |
| FR2923160B1 (fr) * | 2007-11-02 | 2013-07-26 | Pasteur Institut | Composes destines a prevenir ou traiter une infection virale. |
| US10105305B2 (en) * | 2014-02-19 | 2018-10-23 | The Johns Hopkins University | Compositions and methods for promoting skin regeneration and hair growth |
| KR20180101418A (ko) * | 2015-12-31 | 2018-09-12 | 코나터스 파마슈티칼스, 인크. | 간 질환의 치료에서의 카스파제 억제제의 사용 방법 |
| IL248468A0 (en) * | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing |
| EP3609523B1 (en) * | 2017-04-24 | 2022-03-02 | Tsinghua University | Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy |
| AU2019359473B2 (en) * | 2018-10-11 | 2025-11-20 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for cell culture |
| WO2022008597A1 (en) * | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
-
2021
- 2021-03-30 KR KR1020227037574A patent/KR20230006480A/ko not_active Withdrawn
- 2021-03-30 JP JP2022559918A patent/JP2023520460A/ja active Pending
- 2021-03-30 EP EP21779325.6A patent/EP4126010A4/en not_active Withdrawn
- 2021-03-30 CN CN202180034406.XA patent/CN115551536A/zh active Pending
- 2021-03-30 WO PCT/US2021/024889 patent/WO2021202530A1/en not_active Ceased
- 2021-03-30 BR BR112022019850A patent/BR112022019850A2/pt not_active Application Discontinuation
- 2021-03-30 IL IL296890A patent/IL296890A/en unknown
- 2021-03-30 MX MX2022012234A patent/MX2022012234A/es unknown
- 2021-03-30 CA CA3174364A patent/CA3174364A1/en active Pending
- 2021-03-30 AU AU2021245848A patent/AU2021245848A1/en not_active Abandoned
- 2021-03-30 US US17/916,170 patent/US20230218705A1/en not_active Abandoned
-
2023
- 2023-09-29 US US18/477,878 patent/US20240115649A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3174364A1 (en) | 2021-10-07 |
| EP4126010A4 (en) | 2024-04-24 |
| US20240115649A1 (en) | 2024-04-11 |
| US20230218705A1 (en) | 2023-07-13 |
| CN115551536A (zh) | 2022-12-30 |
| IL296890A (en) | 2022-12-01 |
| BR112022019850A2 (pt) | 2023-04-25 |
| KR20230006480A (ko) | 2023-01-10 |
| JP2023520460A (ja) | 2023-05-17 |
| WO2021202530A1 (en) | 2021-10-07 |
| AU2021245848A1 (en) | 2022-12-01 |
| EP4126010A1 (en) | 2023-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| WO2020205473A8 (en) | Compositions and methods for the treatment of kras associated diseases or disorders | |
| MX2018015516A (es) | Inhibidores de papd5 y papd7 para tratar la infeccion por hepatitis b. | |
| BR9916785A (pt) | Tratamento de asma com inibidores mek | |
| EA202192528A1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| MX2023012095A (es) | Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada. | |
| BR112022019850A2 (pt) | Inibidores de caspase para melhorar o reparo de lesões e para tratar infecções bacterianas e virais | |
| WO2022020353A3 (en) | Methods and compositions for treatment and prevention of coronavirus infection | |
| PH12022553501A1 (en) | Alk2 inhibitors for the treatment of anemia | |
| MX2022000545A (es) | Inhibidores de enzimas. | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| BR112022013646A2 (pt) | Método de tratamento de esplenomegalia | |
| MX2025010157A (es) | Metodo de preparacion y uso de un derivado de dihidrotienopirimidina | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| WO2023164455A3 (en) | Compositions and methods to modulate the immune system | |
| PH12019500242A1 (en) | 9-aminomethyl minocycline compounds and uses thereof | |
| MX2024015040A (es) | Fitusiran para el tratamiento de la hemofilia a y b en pacientes pediatricos | |
| WO2020201833A8 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a | |
| MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. |